Acquisition by Scheeren Joseph of 19516 shares of Barinthus Biotherapeutics at 2.34 subject to Rule 16b-3
| BRNS Stock | 0.86 0.03 3.61% |
Slightly above 71 percent of all Barinthus Biotherapeutics' private investors are curious in acquiring. The analysis of the overall investor sentiment regarding Barinthus Biotherapeutics plc suggests that a large number of traders are confidant. Barinthus Biotherapeutics' investing sentiment can be driven by a variety of factors including economic data, Barinthus Biotherapeutics' earnings reports, geopolitical events, and overall market trends.
Barinthus | Build AI portfolio with Barinthus Stock |
Filed transaction by Barinthus Biotherapeutics plc Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Barinthus Biotherapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Barinthus Biotherapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Barinthus Biotherapeutics Fundamental Analysis
We analyze Barinthus Biotherapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Barinthus Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Barinthus Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Barinthus Biotherapeutics is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Barinthus Biotherapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Barinthus Biotherapeutics stock to make a market-neutral strategy. Peer analysis of Barinthus Biotherapeutics could also be used in its relative valuation, which is a method of valuing Barinthus Biotherapeutics by comparing valuation metrics with similar companies.
Peers
Barinthus Biotherapeutics Related Equities
| CTKB | Cytek Biosciences | 4.02 | ||||
| EYE | National Vision | 3.69 | ||||
| FIZZ | National Beverage | 1.98 | ||||
| AMGN | Amgen | 1.85 | ||||
| FMX | Fomento Economico | 0.55 | ||||
| SCSC | ScanSource | 0.02 | ||||
| VMD | Viemed Healthcare | 0.45 | ||||
| XYLO | Xylo Technologies | 0.79 |
Additional Tools for Barinthus Stock Analysis
When running Barinthus Biotherapeutics' price analysis, check to measure Barinthus Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Barinthus Biotherapeutics is operating at the current time. Most of Barinthus Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Barinthus Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Barinthus Biotherapeutics' price. Additionally, you may evaluate how the addition of Barinthus Biotherapeutics to your portfolios can decrease your overall portfolio volatility.